Drug guidance
SGLT2 inhibitors for treating heart failure and chronic kidney disease
Condition
Cardiovascular
Kidney
2 January 2024
Published on 31 Aug 2022
Last Updated on 02 Jan 2024
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Empagliflozin 10 mg and 25 mg tablets
in line with its registered indications for treating heart failure and chronic kidney disease, in view of favourable clinical and cost-effectiveness.
Subsidy status
Empagliflozin 10 mg and 25 mg tablets are recommended for inclusion on the Standard Drug List (SDL) from 1 November 2023.
Of note, dapagliflozin 5 mg and 10 mg tablets will be delisted from the MOH List of Subsidised Drugs with effect from 1 August 2024 due to unfavourable cost-effectiveness compared with empagliflozin.